In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, examines the most common threats to trial data reliability, including opaque methodologies, synthetic controls, and the limits of ...

Geroscience examines the underlying biology of aging to delay chronic diseases and extend the healthy years of human life.

His vision came to fruition in what is now an 80,000 square foot complex with an on-site animal research facility, dedicated regenerative medicine laboratory, expansive infusion area, in-house MRI ...

A narrative review examines how generative AI tools such as large language models and vision-language models could assist precision oncology by interpreting genomic data, matching patients to clinical ...

Clinical trials are the cornerstone of drug innovation in modern medicine, providing a systematic, evidence-based framework for determining the efficacy and safety of treatments before they reach ...

We are pleased to present additional data that further underscore the wide-ranging therapeutic potential of rinvatercept,” said Jasbir S. Seehra, President and Chief Executive Officer of Keros. “These ...

With various challenges impacting the clinical supply chain, existing models are no longer fit-for-purpose and need to adapt.

Polyrizon Ltd. (Nasdaq: PLRZ) ('Polyrizon” or the 'Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a ...

Ketogenic diet therapies, including the classic ketogenic diet, modified Atkins diet, and low glycaemic index treatment, have shown effectiveness in controlling seizures, in part by shifting ...

The Minns Labor Government is providing a funding boost to an Australian-first alliance that's fast-tracking cancer patients across NSW onto ...

Fred D. Lublin, MD, discusses evolving concepts in MS, including earlier high-efficacy therapy, unrecognized progression, and ...

Fred Hutch Cancer Center medical oncologist Dr. Lisa Tachiki has been named a 2025 Cancer Research Fellow by the Kuni Foundation, an honor that includes an unrestricted, two-year $300,000 award.